MedTrace Logo

Mirvaso® Gel and Dysport® for Erythema and Flushing of Rosacea

NCT03508869 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2023-04-18

No results posted yet for this study

Summary

To evaluate the safety and efficacy of Mirvaso® Gel and Dysport® for erythema and flushing of Rosacea.

Conditions

  • Erythema and Flushing Associated With Rosacea

Interventions

DRUG

Mirvaso® (brimonidine) topical gel, 0.33%

Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent facial erythema of rosacea in adults 18 years of age or older.

DRUG

Dysport®

Dysport® is an acetylcholine release inhibitor and a neuromuscular blocking agent.

DRUG

Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%

Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%

Sponsors & Collaborators

  • Galderma R&D

    collaborator INDUSTRY

  • Skin Laser & Surgery Specialists

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-09-27
Primary Completion
2017-09-20
Completion
2017-09-20

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03508869 on ClinicalTrials.gov